SITE011-0299

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-02-23

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-03-26 (study day 23); relationship: not assessed

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-23 (study day 142); relationship: N

severe assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-27 (study day 146); relationship: not assessed

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-08-03 (study day 153); relationship: N

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-10-30 (study day 241); relationship: not assessed

Data queries

No data queries.